Bertino J R, Göker E, Gorlick R, Li W W, Banerjee D
Program of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Stem Cells. 1996 Jan;14(1):5-9. doi: 10.1002/stem.140005.
The mechanisms of intrinsic and acquired resistance to methotrexate (MTX) in human tumors are reviewed herein. In blasts from patients with acute lymphocytic leukemia, resistance mechanisms found are decreased uptake and increased dihydrofolate reductase (DHFR) activity. A major cause of intrinsic resistance to MTX in soft tissue sarcoma cells and in acute myelocytic leukemia appears to be a lack of drug retention, due mainly to low levels of polyglutamylation. A novel association between lack of the retinoblastoma protein and intrinsic MTX resistance has been found. This has been attributed to an increase in DHFR activity, due to an increased rate of transcription of this gene, stimulated by an increase in levels of free E2F, not sequestered by hypophosphorylated retinoblastoma protein.
本文综述了人类肿瘤对甲氨蝶呤(MTX)的内在性和获得性耐药机制。在急性淋巴细胞白血病患者的原始细胞中,发现的耐药机制是摄取减少和二氢叶酸还原酶(DHFR)活性增加。软组织肉瘤细胞和急性髓细胞白血病对MTX内在性耐药的一个主要原因似乎是药物滞留缺乏,这主要是由于聚谷氨酸化水平较低。已发现视网膜母细胞瘤蛋白缺乏与MTX内在性耐药之间存在新的关联。这归因于DHFR活性增加,这是由于该基因转录速率增加所致,而转录速率增加是由游离E2F水平升高刺激的,游离E2F未被低磷酸化的视网膜母细胞瘤蛋白隔离。